NLRX1

Across TCGA pan-cancer cohorts, NLRX1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of NLRX1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where NLRX1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NLRX1 is over-expressed in tumor, although a few such as BRCA and KICH show the opposite, repressed pattern.

LIHC, KIRP, and BRCA are the cancer types where NLRX1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NLRX1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.819	<.001	7	view →
KIRP	All	IV	+0.929	.002	6	view →
BRCA	All	III,IV	−0.756	<.001	6	view →
KICH	All	All	−0.562	.001	6	view →
READ	All	All	−0.576	.001	5	view →
HNSC	All	All	−0.472	.013	4	view →
CHOL	All	All	+1.113	<.001	3	view →
LUSC	All	All	+0.349	.004	3	view →
UCEC	All	All	−0.655	.007	2	view →
LUAD	Male	III,IV	+0.571	.015	1	view →
KIRC	Female	All	+0.274	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

NLRX1–LIHC

Open the LIHC breakdown →